Humacyte’s (HUMA) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research note issued to investors on Friday morning,Benzinga reports. The firm currently has a $25.00 price objective on the stock.

Other analysts have also recently issued research reports about the company. EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a report on Monday, September 9th. HC Wainwright reiterated a “buy” rating and set a $15.00 target price (up from $12.00) on shares of Humacyte in a research report on Friday. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price target on shares of Humacyte in a report on Friday, September 20th. BTIG Research reaffirmed a “buy” rating and set a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. Finally, Benchmark reiterated a “buy” rating and issued a $15.00 target price on shares of Humacyte in a research report on Thursday, October 10th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $13.43.

Humacyte Trading Up 34.1 %

Humacyte stock opened at $4.64 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.10 and a current ratio of 1.10. Humacyte has a fifty-two week low of $2.48 and a fifty-two week high of $9.97. The stock has a market cap of $583.99 million, a P/E ratio of -3.46 and a beta of 1.38. The firm’s fifty day moving average price is $4.83 and its 200-day moving average price is $5.83.

Insider Buying and Selling

In related news, Director Brady W. Dougan sold 427,459 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the transaction, the director now directly owns 1,992,253 shares in the company, valued at $8,646,378.02. This trade represents a 17.67 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Laura E. Niklason sold 811,172 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $4.44, for a total value of $3,601,603.68. Following the completion of the sale, the chief executive officer now owns 2,419,712 shares of the company’s stock, valued at $10,743,521.28. The trade was a 25.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,500,000 shares of company stock worth $6,606,799 in the last 90 days. 11.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Humacyte

Institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new position in shares of Humacyte during the second quarter valued at about $28,000. Concurrent Investment Advisors LLC purchased a new position in Humacyte during the 3rd quarter valued at about $75,000. Principal Financial Group Inc. bought a new position in Humacyte during the 2nd quarter valued at approximately $83,000. FORA Capital LLC purchased a new stake in Humacyte in the 3rd quarter worth approximately $96,000. Finally, Profund Advisors LLC bought a new stake in shares of Humacyte in the 2nd quarter worth approximately $97,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.